MX2009006493A - Compuestos inhibidores activos, citoesqueleticos, de la quinasa de rho, composiciones y usos. - Google Patents

Compuestos inhibidores activos, citoesqueleticos, de la quinasa de rho, composiciones y usos.

Info

Publication number
MX2009006493A
MX2009006493A MX2009006493A MX2009006493A MX2009006493A MX 2009006493 A MX2009006493 A MX 2009006493A MX 2009006493 A MX2009006493 A MX 2009006493A MX 2009006493 A MX2009006493 A MX 2009006493A MX 2009006493 A MX2009006493 A MX 2009006493A
Authority
MX
Mexico
Prior art keywords
cytoskeletal
directed
composition
kinase inhibitor
cytoskeletal active
Prior art date
Application number
MX2009006493A
Other languages
English (en)
Spanish (es)
Inventor
John W Lampe
Saul S Watson
David J Slade
Ward M Peterson
Christopher S Crean
Jason L Vittitow
Jonathan Bryan Decamp
Nicholas F Pelz
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of MX2009006493A publication Critical patent/MX2009006493A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/00781Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2009006493A 2006-12-18 2007-12-18 Compuestos inhibidores activos, citoesqueleticos, de la quinasa de rho, composiciones y usos. MX2009006493A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87055506P 2006-12-18 2006-12-18
US11/958,214 US8071779B2 (en) 2006-12-18 2007-12-17 Cytoskeletal active rho kinase inhibitor compounds, composition and use
PCT/US2007/087973 WO2008077057A2 (en) 2006-12-18 2007-12-18 Cytoskeletal active rho kinase inhibitor compounds, composition and use

Publications (1)

Publication Number Publication Date
MX2009006493A true MX2009006493A (es) 2009-09-10

Family

ID=39537056

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006493A MX2009006493A (es) 2006-12-18 2007-12-18 Compuestos inhibidores activos, citoesqueleticos, de la quinasa de rho, composiciones y usos.

Country Status (11)

Country Link
US (3) US8071779B2 (enExample)
EP (1) EP2099457A4 (enExample)
JP (1) JP5511385B2 (enExample)
KR (1) KR20090091767A (enExample)
CN (2) CN101583361B (enExample)
AU (1) AU2007333715B2 (enExample)
BR (1) BRPI0720457A2 (enExample)
CA (1) CA2672825A1 (enExample)
MX (1) MX2009006493A (enExample)
RU (1) RU2470928C2 (enExample)
WO (1) WO2008077057A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008926A1 (en) 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
CN101282646B (zh) * 2005-07-12 2013-03-27 Dmi生物科学公司 治疗疾病的方法和产品
CA2664335C (en) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
GB2455176A (en) 2007-11-01 2009-06-03 Acucela Inc Amine derivatives useful for treating ophthalmic diseases and disorders
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
MX2010013952A (es) * 2008-06-18 2011-02-18 Inspire Pharmaceuticals Inc Proceso para la preparacion de compuestos inhibidores de rho-quinasa.
US8410147B2 (en) * 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US20090325960A1 (en) * 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
US8299096B2 (en) * 2008-06-26 2012-10-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
US8207195B2 (en) * 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US20100008968A1 (en) * 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP2400969A4 (en) * 2008-12-04 2012-05-16 Inspire Pharmaceuticals Inc METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITORY COMPOUNDS
ES2553827T3 (es) 2009-05-01 2015-12-14 Aerie Pharmaceuticals, Inc. Inhibidores de mecanismo doble para el tratamiento de enfermedad
BRPI1010086A2 (pt) * 2009-06-22 2018-02-06 Dmi Acquisition Corp método e produtos para tratamento de doenças
ES2554688T3 (es) * 2009-06-22 2015-12-22 Ampio Pharmaceuticals, Inc. Procedimiento de tratamiento de enfermedades
AU2015203100B2 (en) * 2009-06-22 2017-03-16 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
EP2512239A4 (en) * 2009-12-14 2014-11-26 Inspire Pharmaceuticals Inc BROKEN BICYCLIC RHO-KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
MX2013000664A (es) * 2010-07-19 2013-03-07 Inspire Pharmaceuticals Inc Compuestos bifuncionales inhibidores de quinasa de rho, composicion y usos.
CA2803689A1 (en) * 2010-07-27 2012-02-02 Inspire Pharmaceuticals, Inc. Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
GB201107223D0 (en) * 2011-04-29 2011-06-15 Amakem Nv Novel rock inhibitors
EP2788472B1 (en) 2011-12-06 2019-02-20 Astellas Institute for Regenerative Medicine Method of directed differentiation producing corneal endothelial cells
JP5977837B2 (ja) 2011-12-21 2016-08-24 ノヴィラ・セラピューティクス・インコーポレイテッド B型肝炎抗ウイルス剤
US20130168825A1 (en) * 2011-12-30 2013-07-04 Alliance For Sustainable Energy, Llc Fabrication of ionic liquid electrodeposited cu-sn-zn-s-se thin films and method of making
MX373711B (es) 2012-08-28 2020-05-08 Janssen Sciences Ireland Uc Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
WO2014068035A1 (en) 2012-10-31 2014-05-08 Amakem Nv Novel rock inhibitors
WO2014100352A1 (en) 2012-12-19 2014-06-26 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
DK2961732T3 (en) 2013-02-28 2017-07-10 Janssen Sciences Ireland Uc SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
HUE061618T2 (hu) 2013-03-15 2023-07-28 Aerie Pharmaceuticals Inc Vegyület szemrendellenességek kezelésére
CN105102451B (zh) 2013-04-03 2018-09-18 爱尔兰詹森科学公司 N-苯基-氨甲酰衍生物及其作为药物用于治疗乙型肝炎的用途
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
DK2997019T3 (en) 2013-05-17 2018-12-03 Janssen Sciences Ireland Uc SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
KR102244937B1 (ko) 2013-07-25 2021-04-27 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 글리옥사미드 치환된 피롤아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도
DK3060547T3 (en) 2013-10-23 2018-01-15 Janssen Sciences Ireland Uc CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EP3102225B1 (en) 2014-02-05 2020-03-25 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2016057306A1 (en) 2014-10-06 2016-04-14 University Of Houston Rho associated kinase (rock) inhibitors and their use in treating disease
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
EP3294871A1 (en) 2015-05-12 2018-03-21 Platod Combination of pharmacological and microfluidic features for improved platelets production
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
KR102579582B1 (ko) 2015-11-17 2023-09-15 에어리 파마슈티컬즈, 인코포레이티드 키나아제 억제제 및 이의 중간체의 제조 방법
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN109640980A (zh) 2016-04-15 2019-04-16 诺维拉治疗公司 包含壳体装配抑制剂的组合和方法
WO2018045091A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
JP2020509004A (ja) * 2017-02-27 2020-03-26 ヤンセン ファーマシューティカ エヌ.ベー. Oga阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている[1,2,4]−トリアゾロ[1,5−a]−ピリミジニル誘導体
JP2020515583A (ja) 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
SG11202002947TA (en) * 2017-11-03 2020-04-29 Aclaris Therapeutics Inc Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
JP2021515769A (ja) 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合調節剤の投薬レジメン
CN108929258A (zh) * 2018-07-09 2018-12-04 张立国 一种Rho激酶抑制剂及其在癌症治疗中的应用
CN108569990A (zh) * 2018-07-09 2018-09-25 张立国 多取代吡咯烷衍生物及其作为Rho激酶抑制剂在癌症中的应用
BR112021002479A2 (pt) 2018-08-10 2021-07-27 Aclaris Therapeutics, Inc. composto, composição farmacêutica, método para inibir a atividade de itk ou jak3 em uma população de células, método para tratar um distúrbio mediado por itk ou jak3 em um indivíduo necessitando do mesmo e uso de um composto
WO2020047229A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020072456A1 (en) * 2018-10-02 2020-04-09 Case Western Reserve University Compounds for treating myelin related disorders
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
AR119732A1 (es) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
CN110215519A (zh) * 2019-07-12 2019-09-10 温州医科大学附属眼视光医院 药物修饰型人工晶状体及其制备方法和应用
CN114133394B (zh) * 2020-08-12 2023-12-08 赛诺哈勃药业(成都)有限公司 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途
MX2024002139A (es) 2021-08-18 2024-03-06 Chemocentryx Inc Arilsulfonil(hidroxi)piperidinas como inhibidores de ccr6.
WO2023023534A2 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl compounds as ccr6 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN116891460A (zh) * 2023-07-12 2023-10-17 浙江大学 一种吲唑类衍生物或其药用盐及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524816A (en) * 1984-02-21 1985-06-25 Dentsply Research & Development Corp. Centrifugal casting furnace
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
EP1378247B1 (en) 2001-04-11 2016-08-24 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
ATE449763T1 (de) 2001-04-16 2009-12-15 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Rhoキナーゼ阻害剤
US6867221B2 (en) 2001-08-30 2005-03-15 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003257588A1 (en) 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
JPWO2004024717A1 (ja) 2002-09-12 2006-01-05 麒麟麦酒株式会社 キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬
ATE536353T1 (de) 2003-08-20 2011-12-15 Vertex Pharma 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
WO2006135383A2 (en) 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006051311A1 (en) * 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
ES2380795T3 (es) * 2005-05-20 2012-05-18 Vertex Pharmaceuticals, Inc. Pirrolopiridinas útiles como inhibidores de proteínas quinasas
CA2615291A1 (en) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives

Also Published As

Publication number Publication date
RU2009127798A (ru) 2011-01-27
CN101583361B (zh) 2013-01-23
US8604218B2 (en) 2013-12-10
WO2008077057A2 (en) 2008-06-26
WO2008077057A3 (en) 2008-08-21
EP2099457A2 (en) 2009-09-16
US20130012543A1 (en) 2013-01-10
US8604205B2 (en) 2013-12-10
JP2010513319A (ja) 2010-04-30
JP5511385B2 (ja) 2014-06-04
BRPI0720457A2 (pt) 2014-01-14
AU2007333715A1 (en) 2008-06-26
RU2470928C2 (ru) 2012-12-27
CA2672825A1 (en) 2008-06-26
CN103254172A (zh) 2013-08-21
KR20090091767A (ko) 2009-08-28
US20120046275A1 (en) 2012-02-23
CN101583361A (zh) 2009-11-18
EP2099457A4 (en) 2011-08-17
US8071779B2 (en) 2011-12-06
AU2007333715B2 (en) 2013-01-10
US20080214614A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
MX2009006493A (es) Compuestos inhibidores activos, citoesqueleticos, de la quinasa de rho, composiciones y usos.
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2011009796A (es) Inhibidores de la cinasa pi3.
EA201170061A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
GT201100181A (es) "inhibidores de proteina cinasa"
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
TN2009000049A1 (en) A pyrrolopyrazin as syk-kinase inhibitor
WO2009155121A3 (en) Inhibitors of pi3 kinase
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MX2009005691A (es) Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
WO2020198055A9 (en) Allosteric bcr-abl proteolysis targeting chimeric compounds
MX2023000521A (es) Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5).
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
ATE502935T1 (de) C-met-proteinkinasehemmer

Legal Events

Date Code Title Description
HH Correction or change in general